Return to study ST000445 main page
MB Sample ID: SA022637
| Local Sample ID: | UNIFESP_lip_LF7 |
| Subject ID: | SU000466 |
| Subject Type: | Human patients (Women) |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Age Or Age Range: | <= 37 years |
| Gender: | Female |
| Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR000480 |
| Treatment Summary: | To induce follicular growth, each of the eligible 14 patients received both rFSH 225 IU alone (Gonal F® [Merck-Serono, Darmstadt, Germany]) (FSH group) and rFSH 225 IU + hMG 75 IU (Menopur® [Ferring, Kiel, Germany]) (Low-dose-LH group) starting on cycle day 2 in two separate cycles (i.e. each patient acted as her own control). Sequential transvaginal ultrasounds were performed from stimulation day 5 onwards. Daily doses of GnRH antagonist analog cetrorelix acetate 0.25 mg (Cetrotide® [Merck-Serono, Darmstadt, Germany]) were administered in both groups when the leading follicle reached a mean diameter of 13 mm until the stimulation day 7, or from day 8. When at least one follicle was greater than 17 mm, 250 mcg of human chorionic gonadotropin (hCG) (Ovidrel® [Merck-Serono, Darmstadt, Germany]) was administered, and oocyte retrieval was scheduled 35-36 hours later. |
| Treatment: | Two types of controlled ovarian stimulation |
| Treatment Compound: | Exogenous gonadotropins to induce follicular growth |
